Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFudan University
About this trial
This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.
Eligibility criteria
Qualifiers
Age 18 and above, regardless of gender;
Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;
Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
No obvious surgical contraindications;
Disqualifiers
Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;
Currently diagnosed with other types of tumors or any cancer history;
Diagnosed with familial syndromes;
Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
Trial design
Treatments tested in this trial
- Blood collection
Treatment groups
1,000 Participants
are divided into 4 treatment groupsSponsors and collaborators
Fudan University
Lead sponsor
West China Hospital
Collaborator
Source ClinicalTrials.gov